Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. This updated presentation time reflects a change from previous announcements. Interested parties can access a live and archived webcast of the presentation on the company’s website under the 'Investors' section. The company focuses on harnessing the adaptive immune system for clinical products aimed at diagnosing and treating diseases, with three commercial products and a robust clinical pipeline.

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 40^th Annual J.P. Morgan Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 10^th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. This presentation time has been updated from a previous announcement and reflects the current schedule. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Schmitt
206-279-2423
media@adaptivebiotech.com

FAQ

When is Adaptive Biotechnologies presenting at the J.P. Morgan Healthcare Conference?

Adaptive Biotechnologies will present on January 10, 2022, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.

How can I access the webcast of Adaptive Biotechnologies' presentation?

You can access the live and archived webcast on the 'Investors' section of Adaptive Biotechnologies’ website.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system to create clinical products for diagnosing and treating diseases.

How many commercial products does Adaptive Biotechnologies have?

Adaptive Biotechnologies currently has three commercial products.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.